Of note, we tested LILRB2 blockade both before and after Mtb infection because patients with TB and MDR-TB can be targeted using mab-B2 immunotherapy, and in addition, people at risk of TB can perhaps be given mab-B2 injections. Here, LILRB2 is linked to multidrug-resistant tuberculosis.